Edesa Biotech (NASDAQ:EDSA – Get Free Report) is projected to post its quarterly earnings results before the market opens on Friday, May 9th. Analysts expect Edesa Biotech to post earnings of ($0.30) per share for the quarter.
Edesa Biotech (NASDAQ:EDSA – Get Free Report) last released its quarterly earnings results on Friday, February 14th. The company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.17). During the same period last year, the firm posted ($0.54) EPS. On average, analysts expect Edesa Biotech to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Edesa Biotech Trading Down 1.7 %
Shares of EDSA opened at $2.28 on Thursday. The stock has a 50 day moving average of $2.35 and a 200 day moving average of $2.26. Edesa Biotech has a 12 month low of $1.55 and a 12 month high of $5.59. The company has a market capitalization of $16.01 million, a price-to-earnings ratio of -1.22 and a beta of 0.55.
Analysts Set New Price Targets
Get Our Latest Research Report on Edesa Biotech
Edesa Biotech Company Profile
Edesa Biotech, Inc, a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis.
Recommended Stories
- Five stocks we like better than Edesa Biotech
- How to Calculate Options Profits
- Survey: America’s Most Inspirational Women Business Leaders [2025]
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- Disney Stock Jumps on Earnings—Is the Magic Sustainable?
- What is a Special Dividend?
- What Oil, Value, and Growth Correlations Say About the Market
Receive News & Ratings for Edesa Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edesa Biotech and related companies with MarketBeat.com's FREE daily email newsletter.